Intra-species extrapolation in risk assessment of different classes of antimicrobials

Human and Ecological Risk Assessment (HERA)

Volumn 7, Issue 1, 2001, Pages 15-36

  Abdel Megeed, Mohamed A ^a   Suh, Duck H ^a   Abdel Rahman, Mohamed S ^a  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

Author keywords

Interindividual variability; Pharmacodynamics; Pharmacokinetics; Risk assessment; Uncertainty factor

Indexed keywords

EID: 23044525173     PISSN: 10807039     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Barnes DG and Dourson MI. 1988. Reference dose (RfD): Description and use in health risk assessment. Regul Toxicol Pharmacol 8:471-86
2. Calabrese EJ. 1985. Uncertainty factors and interindividual variation. Regul Toxicol Pharmacol 5:190-6
3. Chu SY, Wilson DS, Guay DRP, et al. 1992a. Clarithromycin pharmacokinetics in healthy young and elderly volunteers. J Clin Pharmacol 32:1045-9
4. Chu SY, Park Y, Locke C, et al. 1992b. Drug-Food interaction potential of clarithromycin, a new macrolide antimicrobial. J Clin Pharmacol 32:32-6
5. Coyne TC, Shum S, Chun AHC, et al. 1979. Bioavailability of erythromycin ethylsuccinate in pediatric patients. J Clin Pharmacol 18(4):194-202
6. Croteau D, Bergeron MG, and Lebel M 1988. Pharmacokinetic advantage of erythromycin estolate over ethylsuccinate as determined by high-pressure liquid chromatography. Antimicrob Agents Chemother 33(4):561-5
7. Ellner PD, Fink DJ, Neu HC, et al. 1987. Epidemiologic factors affecting antimicrobial resistance of common bacterial isolates. J Clin Microbiol 25 (9): 1668-74
8. Finitzo-Hieber T, McCracken GH, and Brown KC. 1985. Prospective controlled evaluation of auditory function in neonates given netilmicin or amikacin. J Pediatr 106:129-36
9. Gan VN, Chu SY, Kusmiez HT, et al. 1992. Pharmacokinetics of a clarithromycin suspension in infants and children. Antimicrob Agents Chemother 36(11):2478-80
10. Gianni V, Vigliani E, and Assael BM. 1981. Evaluation of the auditory function in children treated with gentamicin in the newborn period. Riv Ital Ped 7:17-20
11. Gilman JT, Gal P, Levine RS, et al. 1986. Factors influencing theophylline disposition in 179 newborns. Ther Drug Monit 8:4-10
12. Ginsburg CM, McCracken GHJr, Petruska M, et al. 1985. Pharmacokinetics and bactericidal activity of cefuroxime axetil. Antimicrob Agents Chemother 28(4), 504-7
13. Grygiel JJ and Brikett DJ. 1980. Effect of age on patterns of theophylline metabolism. Clin Pharmacol Ther 28:456-62
14. Hattis D, Erdreich I, and Ballew M. 1987. Human variability in susceptibility to toxic chemicals-a preliminary analysis of pharmacokinetics data for normal volunteers. Risk Anal 7 (94):415-26
15. Ho KH, Bryson SM, Thiessen JJ, et al. 1995. The effects of age and chemotherapy on gentamicin pharmacokinetics and dosing in pediatric oncology patients. Pharmacother 15(6):754-64
16. IPCS (International Programme in Chemical Safety). 1994. Environmental Health Criteria No. 170: Assessing Human Health Risks of Chemicals: Derivation of Guidance Values for Health Based Exposure Limits. World Health Organization, Geneva
17. Jones RN, Jacobs MR, Washington JA, et al. 1997. A 1994-95 survey of Hemophilus influenza susceptibility to ten orally administered agents. A 187 clinical laboratory center sample in the United States. Diag Microbiol Infect Dis 27(3):75-83
18. Kadry AM, Suh DH, and Abdel-Rahman MS. 1997. Kinetic and dynamic data of analgesics and NSAIDS drugs reduce 10X uncertainty factors. Hum Ecol Risk Assess 3(4):567-78
19. Kahlmeter G and Dahlager J. 1984. Animoglycosides toxicity: a review of clinical studies published between 1975 and 1982. J Antimicrob Chemother 13: Suppl A, 9-22
20. Kerlin P, Zinsmeister A, and Phillips S 1982. Relationship of motility to flow of contents in the human small intestine. Gastroentrol 82:701-6
21. Lackner TE and Birge S. 1990. Accuracy of pharmacokinetic dose determination of gentamicin in geriatric patients. DICP Ann Pharmacother 24:29-32
22. Lehman AJ and Fritzhugh OG. 1954. 100-Fold margin of safety. Assoc Food Drug Off US Q Bull 18:33-5
23. McCracken GHJr, Ginsburg CM, Clashsen JC, et al. 1978. Pharmacologic evaluation of orally administered antibiotics in infants and children: Effects of feeding in bioavailability. Ped 62(5):738-43
24. Miglioli PA, Pivetta P, Strazzabosco M, et al. 1990. Effect of age on single- and multiple-dose pharmacokinetics of erythromycin. Eur J Clin Pharmacol 39:161-4
25. Milsap RL and Szefler SJ. 1986. Special pharmacokinetic considerations in children. In: Evans (ed), Applied Pharmacokinetics: Principles of Therapeutic Drug Monitoring, 2nd ed, pp 294-330. Applied Therapeutics, Spokane, WA
26. Naumann BD, Weideman P, Dixit R, et al. 1997. Use of toxicokinetic and toxicodynamic data to reduce uncertainties when setting occupational exposure limits for pharmaceuticals. Hum Ecol Risk Assess 3(4):555-65
27. NCCLS (National Committee for Clinical Laboratory Standards). 1993. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically: Approved Standards M7-A3. Villanova, PA
28. NCCLS (National Committee for Clinical Laboratory Standards). 1995. Performance Standards for Antimicrobial Susceptibility Testing. Sixth Informational Supplement M100-S6. Villanova, PA
29. Pearlman SA, Duran C, Wood MA, et al. 1989. Caffeine pharmacokinetics in preterm infants older than two weeks. Devleop Pharmacol Ther 12:65-9
30. Radovani EM, Pistolesi C, Fanos V, et al. 1993. Pharmacokinetics of amikacin in neonates. Devleop Pharmacol Ther 20:167-73
31. Redmond CK. 1981. Sensitive population subsets in relation to effects of low doses. Environ Health Perspect 42:137-40
32. Renneberg J, Christensen OM, Thompson NOB, et al. 1993. Cefuroxime concentrations in serum, joint fluid and bone in elderly patients undergoing arthroplastry after administration of cefuroxime axetil. J Antimicrob Chemother 32:751-55
33. Renwick AG. 1991. Safety factors establishment of acceptable daily intakes. Food Add Contam 8:135-50
34. Renwick AG. 1993. Data-derived safety factors for the evaluation of food additives and environmental contaminants. Food Add Contam 10(3):275-305
35. Rowe JW, Andres R, Tobin JD, et al. 1976. The effect of age on creatinine clearance in mean: a cross-sectional and longitudinal study. J Gerontol 31:155-63
36. 2 receptor antagonists. Postgrad Med J 68 (Suppl 3):S3-S9
37. Seidman BC, Brown SL, DeRosa CT, et al. 1991. Sensitive and hypersusceptible populations: Risk assessment considerations for exposure to single chemicals or chemical mixtures. In: Zervos C (ed), Risk Analysis, Prospects and Opportunities, pp 305-13. Plenum Press, NY
38. Suh DH and Abdel-Rahman MS. 1997. Assessing human risks of chemicals and drugs: An Overview. Hum Ecol Risk Assess 3(4):599-615
39. Sutton LD, Biedenbach DJ, Yen A, et al.. 1995. Development, characterization, and initial evaluation of SI. A new chromogenic cephalosporin for beta-lactamase detection. Diag Microbiol Infect Dis 21:1-8
40. Triggs EJ, Johnson JM and Learoyd B. 1980. Absorption and disposition of ampicillin in the elderly. Eur J Clin Pharmacol 18:195-8
41. USEPA (U.S. Environmental Protection Agency). 1996. Is an additional uncertainty actor necessary and appropriate to assess pre- and postnatal developmental and reproductive effects in infants and children exposed to pesticides through chronic dietary exposure?
42. Vestal RE and Dawson GW. 1985. Pharmacology and aging. In: Finch EC and Schneider EL (eds), Handbook of the Biology of Aging, 2nd ed, pp 744-819. Van Nostrand Reinhold, NY
43. Wynne HA, Cope LH, Mutch E, et al. 1989. The effect of age upon liver volume and apparent liver blood flow in healthy men. Hepatol 9:297-301
44. Yasuhara H, Kobayashi S, Sakamoto K, et al. 1982. Pharmacokinetics of amikacin and cephalothin in bedridden elderly patients. J Clin Pharmacol 22:403-9
45. Young BCK and Sostre S. 1994. Kidney to liver ratio: A simple scintigraphic parameter for routine individual renal function assessment in children. Clin Nucl Med 19:288-32